IBER.U (Ibere Pharmaceuticals) Net Income From Continuing Operations : $6.19 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Ibere Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Ibere Pharmaceuticals's net income from continuing operations for the three months ended in Sep. 2022 was $0.79 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2022 was $6.19 Mil.

Ibere Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Ibere Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibere Pharmaceuticals Net Income From Continuing Operations Chart

Ibere Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Net Income From Continuing Operations

1.56

Ibere Pharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Net Income From Continuing Operations	Get a 7-Day Free Trial			1.73	0.35	3.57	1.47	0.79

Ibere Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.19 Mil.

Ibere Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ibere Pharmaceuticals (NYSE:IBER.U) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

2005 Market Street, Suite 2030, Philadelphia, PA, USA, 19103

Website

https://www.iberepharma.com

Ibere Pharmaceuticals is a blank check company.

Executives

Elaine V Jones	director	C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Osagie O Imasogie	director, 10 percent owner, officer: Chief Executive Officer
Calvin B. Johnson	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Zoltan Kerekes	director, 10 percent owner, officer: Chief Operating Officer	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Louis J. Vollmer	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Lisa M. Gray	director, 10 percent owner, officer: Chief Financial Officer	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Henrietta Ukwu	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Pipv Capital Llc	10 percent owner	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103

Ibere Pharmaceuticals Headlines

From GuruFocus

Ibere Pharmaceuticals Receives Expected NYSE Notice Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 05-28-2021

Ibere Pharmaceuticals Announces Closing of $138,000,000 Initial Public Offering

By PRNewswire PRNewswire • 03-03-2021